NASPCC

New Aetna Policy for PSMA Screening for PLUVICTO Radioligand Therapy ow.ly/s46050JVtX3

Web-Based Peer Navigation for Men with Prostate Cancer and Their Family Caregivers: A Pilot Feasibility Study. ow.ly/k5xj50JVtWm

Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. ow.ly/vjpE50JVtVJ

Neurotoxicities of Novel Non-Steroidal Anti-Androgens for Prostate Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract ow.ly/hv0e50JVtVo

Variability in Testosterone Measurement Between Radioimmunoassay (RIA), Chemiluminescence Assay (CLIA) and Liquid Chromatography-Tandem Mass Spectrometry (MS) Among Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) - Beyond the Abstract ow.ly/nw8v50JVtUs

Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. ow.ly/327v50JVtTI

Fusion heralds FDA tumor therapy clearance ow.ly/zNhT50JVtTj

Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719). ow.ly/tjgv50JVtSE

Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes. ow.ly/Bc5M50JVtRQ

Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. ow.ly/UGpa50JVtRa

Two Specialists, Two Recommendations: Discordance between Urologists' & Radiation Oncologists' Prostate Cancer Treatment Recommendations. ow.ly/PwhL50JVtQU

Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. ow.ly/gTCv50JVtQp

Transperineal vs Transrectal Prostate Biopsy: Is One Better? ow.ly/rX1W50JVtPP

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial ow.ly/BkHJ50JVtOW

Variation and Disparity in the Use of Prostate Cancer Risk Stratification Tools in the United States. ow.ly/L6hL50JVtOJ

PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. ow.ly/393x50JVtOs

EAU 2022: Metastatic Prostate Cancer: Possible Synergies Between Radioligand and Systemic Treatment in M1 Prostate Cancer? Future Perspectives ow.ly/cSeV50JVtOg

EAU 2022: Recurrent Prostate Cancer: Salvage Treatment Options for the PSMA Avid Lesion - Radiotherapy ow.ly/hYaf50JVtNy

EAU 2022: Recurrent Prostate Cancer: Treatment Landscape of Hormone Sensitive Recurring M1 Prostate Cancer ow.ly/GG3g50JVtMx

EAU 2022: Lifetime Risk of Prostate Cancer Death Among High-Risk Germline Mutation Carriers ow.ly/t3ME50JVtLT